Anne Claire Hardy-Bessard
Overview
Explore the profile of Anne Claire Hardy-Bessard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
73
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tougeron D, Seitz-Polski B, Hentzien M, Bani-Sadr F, Bourhis J, Ducreux M, et al.
Bull Cancer
. 2021 Apr;
108(6):614-626.
PMID: 33902918
The COVID-19 pandemic has a major impact at all stages of cancer treatment. Risk of death from COVID-19 in patients treated for a cancer is high. COVID-19 vaccines represent a...
2.
Colomban O, Tod M, Leary A, Ray-Coquard I, Lortholary A, Hardy-Bessard A, et al.
Clin Cancer Res
. 2019 Apr;
25(17):5342-5350.
PMID: 30936122
Purpose: Regarding cancer antigen 125 (CA-125) longitudinal kinetics during chemotherapy, the actual predictive value of the Gynecologic Cancer Intergroup (GCIG) CA-125 response criterion is questioned. The modeled CA-125 elimination rate...
3.
Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard A, et al.
JAMA Oncol
. 2019 Feb;
5(5):623-632.
PMID: 30703190
Importance: Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting. Objective: To...
4.
Floquet A, Berton-Rigaud D, Ferron G, Freyer G, Hardy-Bessard A, You B
Bull Cancer
. 2017 Jun;
104 Suppl 1:S24-S31.
PMID: 28625312
Despite large improvements in treatment efficacy, the cure rate of ovarian cancer has not radically changed. Relapses both remain frequent and are still synonymous with chronic disease. Most of them...
5.
Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe L, Hardy-Bessard A, et al.
J Clin Oncol
. 2005 Mar;
23(15):3343-51.
PMID: 15738542
Purpose: Mitoxantrone-corticosteroid is currently the standard palliative treatment in hormone-refractory prostate cancer (HRPC) patients. Recent clinical trials documented the high activity of the docetaxel-estramustine combination. We conducted a randomized phase...